Pre-clinical studies of sabizabulin to treat prostate cancer and TNBC, and now in HER2+ breast cancer, confirm its safety, its low nanomolar potency, its ability to inhibit primary tumor growth, and lung metastasis, and its ability to induce apoptosis, and evade taxane-resistance [39,42,43,44]. The gene discussed is ERBB2; the disease is breast carcinoma.